Clinical trials: Lymph Node Positive
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial
This phase I trial studies the performance, including ultrasound visibility, of an optimized ultrasound twinkling marker in imaging lymph nodes in patients with clinically node-positive breast cancer.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma
- Trial name
- NCT06999798
- Testing
- Diagnostic Mammography, Resection, Ultrasound Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Breast Cancer (Triple Negative Breast Cancer (TNBC)), Breast Cancer
Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer
The neoadjuvant system therapy (NAST) can significantly increase the pathological complete response (pCR) rate for patients with triple-negative (TNBC) and HER2-positive breast cancer.
- Trial name
- NCT07498400
- Testing
- Exemption of SLNB
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Xijing Hospital
HIV Infections
A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
The purpose of this study is to determine the safety of anti-HIV drugs combined with low-dose chemotherapy (consisting of cyclophosphamide [CTX]) in HIV-positive patients.
- Trial name
- NCT00000899
- Testing
- Nelfinavir mesylate, Lamivudine, Filgrastim
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Breast Cancer Female
Selective Axillary Dissection After Neoadjuvant Chemotherap Yin Patients With Lymphnode-positive Breast Cancer
The aim of this observational study is to collect data regarding the selective axillary dissection tecnique of lymphnode restaging after neoadjuvant chemotherapy in patients with Breast Cancer that is lymphonode positive at the…
- Trial name
- CLYP (NCT07828925)
- Where
- Italy
- Volunteers
- 105 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
Premarking of Axillary Nodes Before Start of Neoadjuvant Chemotherapy Using Magnetic Approach
Breast cancer is one of the commonest types of cancers in females. Treatments include surgery followed by anti-estrogen therapy, radiotherapy and chemotherapy.
- Trial name
- SENTINEO (NCT05625698)
- Testing
- MagTrace only, MagTrace and Magseed
- Where
- Sweden
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Stage II Breast Cancer, Stage IIIA Breast Cancer
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and…
- Trial name
- NCT01901094
- Testing
- Axillary Lymph Node Dissection (ALND), Nodal Radiation Therapy, Axillary Radiation Therapy
- Where
- 1,246 sites in United States, Canada and 1 more
- Volunteers
- 2,012 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Tuberculous Lymphadenitis, Cervical
Steroids vs Placebo in Treatment of Tuberculous Lymphadenitis
This study will be conducted as a single blinded randomized control trial. The goal of this clinical trial is to learn about the role of low dose steroids in the resolution of tuberculous lymphadenitis.
- Trial name
- NCT06236152
- Testing
- Ferrous sulfate, Deltacortril
- Where
- Pakistan
- Volunteers
- 140 people
- Sponsor
- Fahad Javed Awan
HER2-positive Breast Cancer, Stage I Breast Cancer
Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy
This is a prospective, single arm, open-label, unicenter, exploratory study in women with primary operable HER2-positive, HER2-enriched/ERBB2-high breast cancer according to PAM50 intrinsic subtype and a ERBB2 pre-defined cutoff…
- Trial name
- ELPIS (NCT04578106)
- Testing
- Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Fundacio Clinic Barcelona
Breast Neoplasm, Neoadjuvant Therapy
RISAS Procedure in Node Positive Breast Cancer Following NAC
Chemotherapy in clinically node positive breast cancer patients is increasingly administrated in a neoadjuvant setting. The standard treatment regimen in these cases is then: neoadjuvant chemotherapy (NAC) followed by breast…
- Conditions
- Breast Neoplasm, Neoadjuvant Therapy, Axillary Lymph Nodes, Pathological Complete Response
- Trial name
- RISAS (NCT02800317)
- Testing
- RISAS
- Where
- 14 sites in Netherlands
- Volunteers
- 248 people
- Sponsor
- Erasmus Medical Center
Node-positive Breast Cancer
Evaluation of Targeted Axillary Lymph Node Dissection in Node Positive Breast Cancer Patients Post Neo Adjuvant Therapy
evaluation of targeted axillary lymph node dissection in node positive breast cancer patients post neo adjuvant therapy
- Trial name
- NCT05676866
- Testing
- Targeted axillary lymph node dissection
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assiut University
Breast Cancer
Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002646
- Testing
- fenretinide, tamoxifen citrate
- Where
- 85 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer
Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
This trial will compare 6 versus 12 months of trastuzumab in combination with dose dense docetaxel following FE75C as adjuvant chemotherapy in women with axillary lymph node positive breast cancer overexpressing HER2
- Trial name
- NCT00615602
- Testing
- Docetaxel, Trastuzumab, Epirubicin
- Where
- 10 sites in Greece
- Volunteers
- 489 people
- Sponsor
- Hellenic Oncology Research Group
Prostate Cancer
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate…
- Trial name
- NeoPSMA (NCT06881823)
- Testing
- AAA602, AAA802, Gallium (68Ga) gozetotide
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00007904
- Testing
- filgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
PSMA-Guided Surgery and Tissue-Resident T-Cell Profiling in Node-Positive Prostate Cancer
TACTIC-P is a single-center, prospective, single-arm study in 12 men with biopsy-proven prostate cancer and pelvic lymph-node uptake on preoperative PSMA PET, without bone or visceral metastases, who are scheduled for…
- Trial name
- TACTIC-P (NCT07879820)
- Testing
- PSMA-Radioguided Robot-Assisted Radical Prostatectomy With Extended Pelvic Lymph-Node Dissection
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Niguarda Hospital
Cervical Cancer, Radiation Toxicity
Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00012012
- Testing
- Amifostine trihydrate, Cisplatin, Intracavitary brachytherapy
- Where
- 17 sites in United States
- Volunteers
- 45 people
- Sponsor
- Radiation Therapy Oncology Group
Tuberculosis, Mediastinal and Hilar Lymph Node Enlargement
Diagnostic Performance and Safety of Endobronchial Ultrasound-guided Transbronchial Mediastinal Cryobiopsy in Diagnosing Tuberculous Mediastinal Lymphadenitis: a Randomised Controlled Trial
The goal of this clinical trial is to compare the diagnostic efficacy and safety of Endobronchial Ultrasound-guided Transbronchial Mediastinal Cryobiopsy (EBUS-TBMC) versus standard EBUS-guided Transbronchial Needle Aspiration…
- Trial name
- NCT07459569
- Testing
- EBUS-TBMC, EBUS-TBNA
- Where
- China
- Volunteers
- 108 people
- Sponsor
- China-Japan Friendship Hospital
Breast Cancer
Adjuvant AI Combined With Zoladex
The present study is a randomized open-label -phase III study that aims to compare the efficacy of Zoladex® combined with Aromidex® for 3-2 years after SERMs (tamoxifen and Fareston®) as an adjuvant therapy for 2-3 years with the…
- Trial name
- NCT01352091
- Testing
- Zoladex+AI, TAM
- Where
- China
- Volunteers
- 670 people
- Sponsor
- Fudan University
Primary Breast Cancer
Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy
This is a phase IV, single-center, prospective, open-label, randomized,controlled study
- Trial name
- NCT03270007
- Testing
- Vinorelbine
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Tao OUYANG
Breast Cancer
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
This is an open label, phase III study evaluating the efficacy and safety of Pyrotinib in Combination With Trastuzumab and paclitaxel in patients HER2 Positive and lymph node negative invasive Breast Cancer
- Trial name
- NCT05841381
- Testing
- Pyrotinib, Trastuzumab, Paclitaxel
- Volunteers
- 876 people
- Sponsor
- Fudan University